Reaching consensus on drug resistance conferring mutations (Part 1)

Conclusions ReSeqTB serves as a single repository for the compilation, curation, and validation of existing and newly created sequences and metadata on M. tuberculosis strains and will use the currently reviewed data set, validated by international experts, as a starting point until sufficient new sequence data are accumulated. This initiative is supported by a global partnership of academic institutions, public health agencies, and nongovernmental organizations including the Critical Path Institute, FIND, the World Health Organization, the New Diagnostics Working Group, the U.S. Centers for Disease Control and Prevention, and the National Institute of Allergy and Infectious Diseases and it is financially supported by the Bill & Melinda Gates Foundation. Key strengths of the ReSeqTB Database include the following: • A user-friendly interface designed for nonexpert or expert operability. • A standardized and validated analysis pipeline for variant analyses of M. tuberculosis next-generation sequencing (NGS) data. • Access to data beyond the published literature with dynamic and iterative updates of new data generated by global surveillance and clinical trials. • A well-developed legal structure to ensure intellectual property rights and data ownership remain with contributors. • A structured data-sharing architecture to restrict access to sensitive or unpublished data sets. • Metadata standardization using CDISC: supports global, platform-independent d...
Source: International Journal of Mycobacteriology - Category: Infectious Diseases Source Type: research